Investigational drug · Phase 2
MRG007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Colorectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MRG007"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRG007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRG007" as an intervention, largest first.
ArriVent BioPharma, Inc.Industry
NCT07066657 · 572 participants (planned) · Start Jul 25, 2025 · Primary completion Mar 2028
Drug: MRG007; MRG007 and Bevacizumab · For: Locally Advanced or Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer and 1 more
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 21 sites in all
- A Study of MRG007 Combination Therapy for Advanced Colorectal CancerNot yet recruiting
Lepu Biopharma Co., Ltd.Industry
NCT07737600 · 316 participants (planned) · Start Aug 2026 · Primary completion Dec 2028
Drug: MRG007; 5-Fluorouracil / Leucovorin Calcium and 4 more · For: Advanced Colorectal Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Colorectal Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- B1962Phase 22 trials
Tasly Biopharmaceuticals Co., Ltd. · Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers
- RBS2418Phase 22 trials
Riboscience, LLC. · Metastatic Colorectal Cancer, Advanced Colorectal Cancer, Advanced Unresectable Hepatocellular Carcinoma
- VEGF antibodyPhase 22 trials
Lepu Biopharma Co., Ltd. · Hepatocellular Carcinoma, Advanced Colorectal Cancer
- TL938Phase 21 trial
Teligene US · Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.